Our data, obtained from analysis of serum collected from ovarian cancer-bearing mice treated with CSA-131 and AuP@CSA-131 reveal that administration of compounds, both intravenously and intratumorally, altered the serum IL-6 profile by decreasing its concentration when compared with tumor-bearing animals (Figure 6A). This evidence concerns the gene IL6 and ovarian cancer.